|
1
|
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
|
Lancet Neurol
|
2008
|
6.76
|
|
2
|
Rotenone, paraquat, and Parkinson's disease.
|
Environ Health Perspect
|
2011
|
3.87
|
|
3
|
Solvent exposures and Parkinson disease risk in twins.
|
Ann Neurol
|
2011
|
2.92
|
|
4
|
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease.
|
Neurology
|
2015
|
2.88
|
|
5
|
Urate as a predictor of the rate of clinical decline in Parkinson disease.
|
Arch Neurol
|
2009
|
2.46
|
|
6
|
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker.
|
Mov Disord
|
2013
|
2.32
|
|
7
|
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.
|
Mov Disord
|
2008
|
1.98
|
|
8
|
Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study.
|
BMJ
|
2005
|
1.84
|
|
9
|
Atypical antipsychotics and parkinsonism.
|
Arch Intern Med
|
2005
|
1.66
|
|
10
|
Occupation and risk of parkinsonism: a multicenter case-control study.
|
Arch Neurol
|
2009
|
1.56
|
|
11
|
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.
|
J Neurol Neurosurg Psychiatry
|
2012
|
1.54
|
|
12
|
Early versus delayed bilateral subthalamic deep brain stimulation for parkinson's disease: a decision analysis.
|
Mov Disord
|
2010
|
1.48
|
|
13
|
Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses.
|
Neurology
|
2014
|
1.45
|
|
14
|
Investigation of c9orf72 in 4 neurodegenerative disorders.
|
Arch Neurol
|
2012
|
1.32
|
|
15
|
Pimozide for tics in Tourette's syndrome.
|
Cochrane Database Syst Rev
|
2009
|
1.16
|
|
16
|
Head injury, α-synuclein Rep1, and Parkinson's disease.
|
Ann Neurol
|
2012
|
1.14
|
|
17
|
Protocol for a systematic review of prognosis after mild traumatic brain injury: an update of the WHO Collaborating Centre Task Force findings.
|
Syst Rev
|
2012
|
1.07
|
|
18
|
The curious case of phenocopies in families with genetic Parkinson's disease.
|
Mov Disord
|
2011
|
0.96
|
|
19
|
Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: differential effects on bradykinesia.
|
Mov Disord
|
2007
|
0.95
|
|
20
|
Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better.
|
Mov Disord
|
2014
|
0.94
|
|
21
|
Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome.
|
Am J Med Genet A
|
2015
|
0.91
|
|
22
|
Genetic modification of the association of paraquat and Parkinson's disease.
|
Mov Disord
|
2012
|
0.91
|
|
23
|
Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment.
|
Brain
|
2013
|
0.90
|
|
24
|
Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease.
|
Dement Geriatr Cogn Disord
|
2013
|
0.87
|
|
25
|
Reply to: Gray et al.
|
Mov Disord
|
2014
|
0.84
|
|
26
|
Is there seasonal variation in risk of Parkinson's disease?
|
Mov Disord
|
2007
|
0.82
|
|
27
|
Is chronic levodopa therapy associated with distal symmetric polyneuropathy in Parkinson's disease?
|
Parkinsonism Relat Disord
|
2012
|
0.81
|
|
28
|
Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease.
|
J Hum Genet
|
2011
|
0.81
|
|
29
|
The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins.
|
Mov Disord
|
2008
|
0.80
|
|
30
|
Pergolide associated cardiac valvulopathy based on Ontario administrative data.
|
Can J Neurol Sci
|
2008
|
0.78
|
|
31
|
High-dosage vitamin E supplementation and all-cause mortality.
|
Ann Intern Med
|
2005
|
0.77
|
|
32
|
The pill questionnaire in a nondemented Parkinson's disease population.
|
Mov Disord
|
2012
|
0.76
|
|
33
|
A randomized trial of varenicline (chantix) for the treatment of spinocerebellar ataxia type 3.
|
Neurology
|
2012
|
0.76
|
|
34
|
Orthostatic hypotension in Parkinsonism: What is it and how can we treat it?
|
Mov Disord
|
2015
|
0.76
|
|
35
|
Peptidoglycan recognition protein genes and risk of Parkinson's disease.
|
Mov Disord
|
2014
|
0.76
|
|
36
|
Confounders and intermediaries in case-control study designs: a strategy for distinguishing between the two when measured using the same variable.
|
Pharmacoepidemiol Drug Saf
|
2010
|
0.76
|
|
37
|
The relevance of pre-motor symptoms in Parkinson's disease.
|
Expert Rev Neurother
|
2015
|
0.75
|
|
38
|
Development of a Chronic Care Model for Neurological Conditions (CCM-NC).
|
BMC Health Serv Res
|
2014
|
0.75
|
|
39
|
Author reply to Holford, Vu and Nutt regarding 'Piecing together the puzzle of progression and mortality in Parkinson's disease'.
|
Br J Clin Pharmacol
|
2013
|
0.75
|
|
40
|
Re: Cabergoline versus levodopa monotherapy: a decision analysis.
|
Mov Disord
|
2004
|
0.75
|
|
41
|
Improvement of apathy after levofloxacin treatment: an N-of-1 study.
|
Neurologist
|
2012
|
0.75
|
|
42
|
The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease.
|
Parkinsonism Relat Disord
|
2012
|
0.75
|
|
43
|
Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force.
|
Mov Disord
|
2017
|
0.75
|
|
44
|
Survival and Health Care Use After Deep Brain Stimulation for Parkinson's Disease.
|
Can J Neurol Sci
|
2020
|
0.75
|
|
45
|
Current use of domperidone and co-prescribing of medications that increase its arrhythmogenic potential among older adults: a population-based cohort study in Ontario, Canada.
|
Drugs Aging
|
2014
|
0.75
|
|
46
|
Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study.
|
Drugs Aging
|
2013
|
0.75
|
|
47
|
New thyroxine treatment in older adults beginning lithium therapy: implications for clinical practice.
|
Am J Geriatr Psychiatry
|
2005
|
0.75
|